Characterization of ciprofloxacin resistant Escherichia coli isolates among men undergoing evaluation for transrectal ultrasound guided prostate biopsy

Journal of Urology

Volumn 190, Issue 6, 2013, Pages 2026-2032

  Qi, Chao ^a,b   Malczynski, Michael ^b   Schaeffer, Anthony J ^a   Barajas, Grace ^b   Nadler, Robert B ^a   Scheetz, Marc H ^b,c   Zembower, Teresa R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

Biopsy; Drug resistance, microbial; Fluoroquinolones; Infection; Prostate

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; PROTEIN PARC; QUINOLONE DERIVATIVE; SULTAMICILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; ESCHERICHIA COLI; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROSTATE BIOPSY; PULSED FIELD GEL ELECTROPHORESIS; TRANSRECTAL ULTRASONOGRAPHY; TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY;

EID: 84888639861     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.05.059     Document Type: Article

References (30)

1. Hodge KK, McNeal JE and Stamey TA: Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 1989;142:66.
2. Liss MA: Infection: prostate biopsy-infection and prior fluoroquinolone exposure. Nat Rev Urol 2011;8:592.
3. Carignan A, Roussy JF, Lapointe V et al: Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? Eur Urol 2012;62:453.
4. Loeb S, Carter HB, Berndt SI et al: Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830.
5. Kapoor DA, Klimberg IW, Malek GH et al: Singledose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998;52:552.
6. Aron M, Rajeev TP and Gupta NP: Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000;85:682.
7. Wolf JS Jr, Bennett CJ, Dmochowski RR et al: Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008;179:1379.
8. Zani EL, Clark OA and Rodrigues Netto N Jr: Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 2011;5:CD006576.
9. Drusano GL, Preston SL, Van Guilder M et al: A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000;44:2046.
10. Crawford ED, Haynes AL Jr, Story MW et al: Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. J Urol 1982;127:449.
11. Feliciano J, Teper E, Ferrandino M et al: The incidence of fluoroquinolone resistant infections after prostate biopsyeare fluoroquinolones still effective prophylaxis? J Urol 2008;179:952.
12. Zaytoun OM, Vargo EH, Rajan R et al: Emergence of fluoroquinolone- resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011;77:1035.
13. Hori S, Sengupta A, Joannides A et al: Changing antibiotic prophylaxis for transrectal ultrasoundguided prostate biopsies: are we putting our patients at risk? BJU Int 2010;106:1298.
14. Liss MA, Chang A, Santos R et al: Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol 2011;185:1283.
15. Steensels D, Slabbaert K, De Wever L et al: Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsyeshould we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 2011;18:575.
16. Taylor AK, Zembower TR, Nadler RB et al: Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 2012;187:1275.
17. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing, Twenty-Second Informational Supplement. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute 2012.
18. Clinical and Laboratory Standards Institute: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard M7-A7, 7th ed. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute 2006.
19. Lartigue MF, Leflon-Guibout V, Poirel L et al: Promoters P3, Pa/Pb, P4, and P5 upstream from bla (TEM) genes and their relationship to betalactam resistance. Antimicrob Agents Chemother 2002;46:4035.
20. Qi C, Malczynski M, Parker M et al: Characterization of genetic diversity of carbapenemresistant Acinetobacter baumannii clinical strains collected from 2004 to 2007. J Clin Microbiol 2008;46:1106.
21. Batura D, Rao GG and Nielsen PB: Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJU Int 2010;106:1017.
22. Liss MA, Peeples AN and Peterson EM: Detection of fluoroquinolone- resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. J Clin Microbiol 2010;49:1116.
23. Duplessis CA, Bavaro M, Simons MP et al: Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 2012;79:556.
24. Williamson DA, Roberts SA, Paterson DL et al: Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 2012;54:1406.
25. Liss MA, Peterson EM, Johnston B et al: Prevalence of ST131 among fluoroquinoloneresistant Escherichia coli obtained from rectal swabs before transrectal prostate biopsy. Urology 81:548.
26. Jacoby GA: Mechanisms of resistance to quinolones. Clin Infect Dis 2005;41:S120.
27. Friedman SM, Lu T and Drlica K: Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob Agents Chemother 2001;45:2378.
28. Everett MJ, Jin YF, Ricci V et al: Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother 1996;40:2380.
29. Barnard FM and Maxwell A: Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser (83) and Asp (87). Antimicrob Agents Chemother 2001;45:1994.
30. Lipsky BA, Byren I and Hoey CT: Treatment of bacterial prostatitis. Clin Infect Dis 2010;50:1641.